Search results for: 'software for clinical studi'

The small animal imaging or in vivo preclinical imaging market began to come into existence from the early 1990s when scientists studying biology and disease processes realized that clinical image could help them reduce the cost of research and time span of their animal studies. At present, medical imaging is an important tool in research applicati...

The procedure for accurately identifying a biomarker correlation based on a patient s genetic makeup is complex and relies on the expertise and knowledge of an oncologist, decision-support scientist, or other healthcare professional involved in the matching process. Precision oncology aims to provide oncologists with diagnosis, prognosis, and treat...

This study examines how global multiomics technologies are changing the way that cancer is treated, with a focus on new developments, strategic needs, and future directions. By facilitating thorough tumor characterization, early detection, patient stratification, and real-time monitoring, multiomics—an integrated analysis of genomics, transcriptomi...

Healthcare providers and payers are operating under the pressure of rising healthcare costs, demand for better health outcomes, and the need to improve the digital patient experience. Frost & Sullivan s start-up tracker helps ecosystem participants identify solution providers with offerings that address industry challenges. This start-up tracker pr...

The global medical devices industry was valued at $545.38 billion in 2024 and is expected to reach $801.34 billion in 2029. Companies continue to focus on and invest in new product development to ensure long-term and sustained growth. The cardiovascular devices market attracted significant investments, especially in transcatheter technologies for m...

The rising global prevalence of neurodegenerative diseases (NDDs) is driving the shift from symptom-to-disease-modifying therapeutics that target unique pathological mechanisms, such as protein misfolding, neuroinflammation, and synaptic dysfunction, and customizing treatment based on unique genetic profiles, disease subtypes, and distinct biomarke...

Qualified respondents to this Frost & Sullivan survey were invited to participate in a telephone interview examining their laboratory’s product purchasing process in 2024 and expectations for 2025. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. The survey provides companies with actionable and trendin...

Qualified respondents to this Frost & Sullivan survey were invited to participate in an online survey examining their laboratory’s product purchasing process in 2025 and expectations for 2026. Frost & Sullivan has conducted similar studies among the same target respondent groups since 2012. The survey provides companies with actionable trend insigh...

Immuno-oncology (I-O) therapies target tumors by harnessing the host s immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, includ...